title: Sequencing systemic therapies for metastatic kidney cancer.
abstract: Defining the appropriate sequencing of therapies for metastatic renal cell carcinoma (mRCC) has become increasingly complex in recent years given the approval of multiple targeted therapies. These targeted therapies fall into 2 broad mechanistic categories: (1) inhibitors of the mammalian target of rapamycin (mTOR), and (2) vascular endothelial growth factor (VEGF)-directed agents. In the current manuscript, data from relevant trials are reviewed to provide a context in which to use these agents across the first- and second-line setting. Strategies to incorporate promising agents currently in late stage development for mRCC are also described.
  Currently, there is no consensus as to the optimal sequence of therapies for patients with metastatic renal cell carcinoma (mRCC). While interleukin-2 (IL-2) and temsirolimus are potential considerations for selected patients in the first-line setting, the majority of patients in this setting are likely candidates for vascular endothelial growth factor (VEGF)-directed therapies. Specifically, these therapies include sunitinib, pazopanib, and bevacizumab/interferon-α. Using the comparative data discussed herein, the relative merits of each should be discussed. In the second-line setting (following VEGF-directed therapy), axitinib, and everolimus are supported by phase III data. There is no data directly comparing the 2 agents-however, studies reviewed in the current manuscript (comparing VEGF- and mammalian target of rapamycin [mTOR]-directed approaches in the second-line setting) can potentially be used to inform clinical decision making.
authors: Department of Medicine, University of Arizona Cancer Center, Phoenix, AZ, USA.
authors: Parminder
authors: P
authors: Singh
authors: Neeraj
authors: N
authors: Agarwal
authors: Sumanta K
authors: SK
authors: Pal
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D019468:Disease Management; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000556:secondary*
chemical_list: D000970:Antineoplastic Agents
references: Urol Oncol. 2016 May;34(5):250-1
references: 25937425
references: N Engl J Med. 2014 May 1;370(18):1769-70
references: 24785224
references: J Clin Oncol. 2014 Mar 10;32(8):760-7
references: 24297950
references: N Engl J Med. 2007 Jan 11;356(2):115-24
references: 17215529
references: Clin Adv Hematol Oncol. 2014 Feb;12(2):90-9
references: 24892254
references: J Clin Oncol. 2014 May 10;32(14 ):1412-8
references: 24687826
references: J Clin Oncol. 2010 Jun 10;28(17 ):e284-5; author reply e286-7
references: 20439632
references: Lancet. 2011 Dec 3;378(9807):1931-9
references: 22056247
references: Mol Cancer Ther. 2010 Dec;9(12):3115-25
references: 21078774
references: J Clin Oncol. 2002 Jan 1;20(1):289-96
references: 11773181
references: J Clin Oncol. 2010 May 1;28(13):2144-50
references: 20368553
references: J Clin Oncol. 1995 Mar;13(3):688-96
references: 7884429
references: Lancet. 2008 Aug 9;372(9637):449-56
references: 18653228
references: J Clin Oncol. 2010 Feb 20;28(6):1061-8
references: 20100962
references: N Engl J Med. 2013 Aug 22;369(8):722-31
references: 23964934
references: Clin Cancer Res. 2014 Jul 1;20(13):3411-21
references: 24658158
references: Ann Oncol. 2013 Feb;24(2):343-9
references: 23022995